Multiple Myeloma

1.5 Credits / Hematology, Hematologic Cancer, Oncology

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Oncology, Hematology, Hematologic Cancer

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

More News

October 14th 2022

Study Identifies Lenalidomide-Carfilzomib as Best Maintenance Treatment Option in MM

Within a selection of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group.

October 10th 2022

PCPs Can Pave Way to Faster Diagnosis of Multiple Myeloma

Jaime Rosenberg

Researchers highlighted the opportunities primary care providers (PCPs) have to promote favorable outcomes through prompt diagnosis as well as help reduce racial disparities in multiple myeloma.

October 6th 2022

Study Evaluates Factors Related to HRQOL in Multiple Myeloma

Regular assessments of patient-reported outcomes (PROs) are important to deliver the best clinical care, including the monitoring health-related quality of life (HRQOL), researchers reported.

Ajay Nooka, MD, MPH, FACP, Winship Cancer Institute

September 16th 2022

Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions

Laura Joszt, MA Skylar Jeremias

Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

September 12th 2022

CAR T-Cell Therapy a Story of Opportunities and Challenges in MM

Jared Kaltwasser

Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.

September 9th 2022

Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?

For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival

September 5th 2022

How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Laura Joszt, MA Skylar Jeremias

Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

September 2nd 2022

Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory

Laura Joszt, MA Skylar Jeremias

Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.

August 27th 2022

Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years

Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

August 19th 2022

Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care

Maggie L. Shaw

This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).

August 12th 2022

QOL Tool Valuable in Identifying Patients’ Chief Concerns

Julia Bonavitacola

A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.

August 10th 2022

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.

August 6th 2022

Rare MM Case Underscores Need to Consider Differential Diagnoses

Maggie L. Shaw

In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.

August 4th 2022

NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression

Maggie L. Shaw

Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.

July 28th 2022

Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment

Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.

July 18th 2022

With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients

A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.

July 16th 2022

Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma

Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.

July 12th 2022

Age, Infection, Cardiac Disease Linked to Early Death for Patients With Newly Diagnosed Multiple Myeloma

Results from a registry study of patients from Australia and New Zealand show that 9.1% of patients with a new diagnosis of multiple myeloma die within a year of diagnosis, and infection contributed to early death in 38% of cases in which a cause of death was reported.

July 9th 2022

Index Finds Half of MM, CLL Patients in Study Had Financial Difficulty

Financial difficulty during treatment for multiple myeloma (MM) or chronic lymphocytic leukemia (CLL) was associated with lower levels of education, incomes below $60,000, and multiple comorbidities.

July 2nd 2022

Review of MM Treatment Landscape Compares Clinical Trials With Real-World Results

Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.

July 1st 2022

Exploring Genomic and Transcriptomic Changes Throughout Multiple Myeloma Progression

Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.

June 28th 2022

Discussing The Future of the RRMM Treatment Landscape

Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.

June 28th 2022

Improving Payer Education on RRMM Therapy

Professional experts offer suggestions on how payers can be further educated on RRMM treatment.

June 28th 2022

How Do IMiDs Fare In Comparison With Emerging RRMM Treatment Options?

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.

June 25th 2022

Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM

Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).

June 21st 2022

Ways Institutions Can Support RRMM Treatment Selection

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

June 21st 2022

Using Lenalidomide and Pomalidomide in RRMM Management

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

June 19th 2022

Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma

Lindsey Mulrooney

Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.

June 18th 2022

Review Highlights Nanomedicine as Potential Drug Delivery Strategy in Multiple Myeloma